Kayexalate, a common therapy for hyperkalemia, has been implicated in bowel necrosis including cases of perforation and death. Despite the seriousness of this effect, the literature describing the pathological and clinical features is very limited, and the dose and time course of the Kayexalate administration is not well characterized. The goal of this study is to assess the association between Kayexalate and the development of bowel necrosis and to describe all cases of Kayexalate-associated injury encountered at our health system. Design: A retrospective review of electronic medical records was performed in a large health system over a six year period (2012- 2018). Clinical record was reviewed for all patients in whom Kayexalate crystals ...
Introduction: A histologic diagnosis of chronic colitis raises a relatively limited differential dia...
BACKGROUND: Microscopic colitis (MC) is a chronic bowel disorder characterised by watery diarrhoea. ...
Background & AimsNephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therap...
Kayexalate, a common therapy for hyperkalemia, has been implicated in bowel necrosis including cases...
Case Presentation: A 73 year-old female with a history of recurrent DVT’s on Warfarin, microscopic p...
AbstractKayexalate (sodium polystyrene sulfonate) is a cation-exchange resin used to treat patients ...
BACKGROUND: Kayexalate (sodium polystyrene sulphonate) in sorbitol ...
Hyperkalemia is one of the most common electrolyte abnormalities encountered in clinical practice. T...
Small intestine diverticulosis is a rare entity that is asymptomatic in the majority of cases. Howev...
Hyperkalemia is a frequent electrolyte disturbance in patients on dialysis or non-dialysis CKD patie...
Kayexalate has been used in the USA since 1975 for the treatment of hyperkalemia. Prior case reports...
Background: Hyperkalemia is a commonly encountered medical problem. The treatment of hyperkalemia in...
BACKGROUND AND AIMS: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) th...
Aliment Pharmacol Ther 2010; 32: 1124-1128 SUMMARY: Background Microscopic colitis causes chronic wa...
Background and Aims: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) th...
Introduction: A histologic diagnosis of chronic colitis raises a relatively limited differential dia...
BACKGROUND: Microscopic colitis (MC) is a chronic bowel disorder characterised by watery diarrhoea. ...
Background & AimsNephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therap...
Kayexalate, a common therapy for hyperkalemia, has been implicated in bowel necrosis including cases...
Case Presentation: A 73 year-old female with a history of recurrent DVT’s on Warfarin, microscopic p...
AbstractKayexalate (sodium polystyrene sulfonate) is a cation-exchange resin used to treat patients ...
BACKGROUND: Kayexalate (sodium polystyrene sulphonate) in sorbitol ...
Hyperkalemia is one of the most common electrolyte abnormalities encountered in clinical practice. T...
Small intestine diverticulosis is a rare entity that is asymptomatic in the majority of cases. Howev...
Hyperkalemia is a frequent electrolyte disturbance in patients on dialysis or non-dialysis CKD patie...
Kayexalate has been used in the USA since 1975 for the treatment of hyperkalemia. Prior case reports...
Background: Hyperkalemia is a commonly encountered medical problem. The treatment of hyperkalemia in...
BACKGROUND AND AIMS: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) th...
Aliment Pharmacol Ther 2010; 32: 1124-1128 SUMMARY: Background Microscopic colitis causes chronic wa...
Background and Aims: Nephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) th...
Introduction: A histologic diagnosis of chronic colitis raises a relatively limited differential dia...
BACKGROUND: Microscopic colitis (MC) is a chronic bowel disorder characterised by watery diarrhoea. ...
Background & AimsNephrotoxicity is a rare idiosyncratic reaction to 5-aminosalicylate (5-ASA) therap...